Literature DB >> 12554671

Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects.

George Zachos1, Michael D Rainey, David A F Gillespie.   

Abstract

The conserved protein kinase Chk1 is believed to play an important role in checkpoint responses to aberrant DNA structures; however, genetic analysis of Chk1 functions in metazoans is complicated by lethality of Chk1-deficient embryonic cells. We have used gene targeting to eliminate Chk1 function in somatic DT40 B-lymphoma cells. We find that Chk1-deficient DT40 cells are viable, but fail to arrest in G(2)/M in response to and are hypersensitive to killing by ionizing radiation. Chk1-deficient cells also fail to maintain viable replication forks or suppress futile origin firing when DNA polymerase is inhibited, leading to incomplete genome duplication and diminished cell survival after release from replication arrest. In contrast to embryonic cells, however, Chk1 is not required to delay mitosis when DNA synthesis is inhibited. Thus, Chk1 is dispensable for normal cell division in somatic DT40 cells but is essential for DNA damage-induced G(2)/M arrest and a subset of replication checkpoint responses. Furthermore, Chk1-dependent processes promote tumour cell survival after perturbations of DNA structure or metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554671      PMCID: PMC140744          DOI: 10.1093/emboj/cdg060

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  45 in total

1.  Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation.

Authors:  N Takao; H Kato; R Mori; C Morrison; E Sonada; X Sun; H Shimizu; K Yoshioka; S Takeda; K Yamamoto
Journal:  Oncogene       Date:  1999-11-25       Impact factor: 9.867

2.  The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation.

Authors:  P Chen; C Luo; Y Deng; K Ryan; J Register; S Margosiak; A Tempczyk-Russell; B Nguyen; P Myers; K Lundgren; C C Kan; P M O'Connor
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

Review 3.  The G2-phase DNA-damage checkpoint.

Authors:  M J O'Connell; N C Walworth; A M Carr
Journal:  Trends Cell Biol       Date:  2000-07       Impact factor: 20.808

4.  The spatial position and replication timing of chromosomal domains are both established in early G1 phase.

Authors:  D S Dimitrova; D M Gilbert
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

5.  Mik1 levels accumulate in S phase and may mediate an intrinsic link between S phase and mitosis.

Authors:  P U Christensen; N J Bentley; R G Martinho; O Nielsen; A M Carr
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

6.  ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.

Authors:  H Zhao; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.

Authors:  W Clark; E J Black; A MacLaren; U Kruse; N LaThangue; P K Vogt; D A Gillespie
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

8.  The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

Authors:  E C Busby; D F Leistritz; R T Abraham; L M Karnitz; J N Sarkaria
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

9.  Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice.

Authors:  H Takai; K Tominaga; N Motoyama; Y A Minamishima; H Nagahama; T Tsukiyama; K Ikeda; K Nakayama; M Nakanishi; K Nakayama
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

10.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

Authors:  Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

View more
  99 in total

1.  Chk1 promotes replication fork progression by controlling replication initiation.

Authors:  Eva Petermann; Mick Woodcock; Thomas Helleday
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

2.  Arabidopsis T-DNA insertional lines for CDC25 are hypersensitive to hydroxyurea but not to zeocin or salt stress.

Authors:  Natasha D Spadafora; John H Doonan; Robert J Herbert; M Beatrice Bitonti; Emily Wallace; Hilary J Rogers; Dennis Francis
Journal:  Ann Bot       Date:  2010-07-20       Impact factor: 4.357

3.  Chk1-dependent S-M checkpoint delay in vertebrate cells is linked to maintenance of viable replication structures.

Authors:  George Zachos; Michael D Rainey; David A F Gillespie
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

4.  Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress.

Authors:  Rene Rodriguez; Mark Meuth
Journal:  Mol Biol Cell       Date:  2005-11-09       Impact factor: 4.138

5.  The fission yeast Crb2/Chk1 pathway coordinates the DNA damage and spindle checkpoint in response to replication stress induced by topoisomerase I inhibitor.

Authors:  Ada Collura; Joel Blaisonneau; Giuseppe Baldacci; Stefania Francesconi
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1.

Authors:  Sinny Delacroix; Jill M Wagner; Masahiko Kobayashi; Ken-ichi Yamamoto; Larry M Karnitz
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

7.  Promoter hijack reveals pericentrin functions in mitosis and the DNA damage response.

Authors:  Yifan Wang; Tiago J Dantas; Pierce Lalor; Peter Dockery; Ciaran G Morrison
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

8.  Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Authors:  Judith E Karp; Brian M Thomas; Jacqueline M Greer; Christopher Sorge; Steven D Gore; Keith W Pratz; B Douglas Smith; Karen S Flatten; Kevin Peterson; Paula Schneider; Karen Mackey; Tomoko Freshwater; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Douglas E Gladstone; Margaret M Showel; Sabine Loechner; David A Parry; Jo Ann Horowitz; Randi Isaacs; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

9.  Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication.

Authors:  Hiroyasu Sakai; Hidetsugu Fujigaki; Sharlyn J Mazur; Ettore Appella
Journal:  Cell Cycle       Date:  2014-01-31       Impact factor: 4.534

10.  Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Authors:  Joleen Hubbard; Charles Erlichman; David O Toft; Rui Qin; Bridget A Stensgard; Sara Felten; Cynthia Ten Eyck; Gretchen Batzel; S Percy Ivy; Paul Haluska
Journal:  Invest New Drugs       Date:  2010-01-15       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.